What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
CagriSema has demonstrated exceptional short- to medium-term efficacy in promoting weight loss, achieving a mean body weight change of -20.4% in the phase 3 REDEFINE 1 trial compared to -3.0% with placebo. This significant difference indicates a major therapeutic advance, supported by robust phase 3 evidence.
Does the economic case hold at the expected price? — Cost effectiveness
No cost-effectiveness data or economic models have been published for CagriSema, leaving a significant gap in understanding its economic value. Without any evidence of cost-effectiveness, it is deemed non-cost-effective at this stage.
Is there quality-of-life evidence payers weigh? — Quality of life
Significant improvements in HRQoL were observed, particularly in physical functioning scores, with a +11.9 point increase in the IWQOL-Lite-CT score compared to placebo. This indicates strong quality-of-life gains, although broader QoL domains were not measured.
Does the safety profile hold up for payers? — Safety and Adverse Effects
CagriSema has a favorable safety profile, with predominantly mild to moderate gastrointestinal side effects reported in 79.6% of patients. The low discontinuation rate due to adverse events (6-8%) indicates good tolerability, aligning with existing GLP-1 therapies.
Was the drug compared against what payers expect? — Comparator Selection
The trials included relevant comparators, including placebo and semaglutide, which are standard in obesity management. This comprehensive approach strengthens the evidence by allowing direct comparisons to current standard-of-care treatments.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial populations were large and representative of the intended user groups, including adults with obesity and type 2 diabetes. Subgroup analyses showed consistent efficacy across different demographics, enhancing generalizability.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
CagriSema can be integrated into existing care pathways without requiring new diagnostic procedures. The administration method is similar to current GLP-1 therapies, suggesting a seamless fit into clinical practice.
Are the wider system costs understood? — Resource Use and Cost Implications
There is a lack of direct data on resource use and cost implications for CagriSema. The anticipated high cost of the drug, combined with the absence of economic evaluations, leads to uncertainty regarding its budget impact.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is derived from multiple rigorous phase 3 RCTs with low bias and high consistency across studies. The robust design and peer-reviewed publications support the credibility of the findings.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While the core trial results are solid, there are uncertainties regarding long-term maintenance of weight loss and the economic implications of widespread use. These factors introduce some risk but are not critical flaws.
